Share Buyback in H. Lundbeck A/S
During any one single trading day a maximum of 25% of the average
daily trading volume of Lundbeck shares on OMX Nordic Exchange
Copenhagen, calculated over 20 days prior to each trading date, will
be bought back, as the share buyback program is implemented in
accordance with the provisions of the European Commission's
regulation no. 2273/2003 of December 22, 2003.
At least once every seven trading days, Lundbeck will issue an
announcement in respect of the transactions made under the program.
The following transactions have been made under the program:
No. of shares Average Transaction value
purchase price (DKK)
(DKK)
Accumulated, last 25,570,279 135.8873 3,474,674,981
announcement
19 December 2007 120,446 145.2557 17,495,463.59
20 December 2007 118,975 144.1059 17,145,005.01
21 December 2007 -- -- --
27 December 2007 -- -- --
28 December 2007 -- -- --
2 January 2008 -- -- --
3 January 2008 -- -- --
Accumulated under the 25,809,700 135.9689 3,509,315,449
program
Following the above buyback it is hereby announced that Lundbeck owns
a total of 6,652,913 own shares at a nominal value of DKK 5, equal to
3.21% of the total number of 207,279,631 shares.
As of January 2008, Lundbeck has appointed Danske Markets (Division
of Danske Bank A/S) as lead manager of the share buyback program.
Danske Markets will, under a separate agreement with the company, buy
back shares on behalf of Lundbeck and make trading decisions in
respect of Lundbeck shares independently of and without influence
from Lundbeck as to the timing of the purchases, as well as carry
through the buyback within the framework set out.
The content of this release will have no influence on the Lundbeck
Group's financial results for the 2007 financial year, due to be
announced on 4 March 2008. On the same occasion, Lundbeck will
present its financial guidance for 2008.
Lundbeck contacts
Investors: Media:
Jacob Tolstrup Anders Schroll
Director, Corporate Reporting Head of Communication
+45 36 43 30 79 +45 36 43 20 81
Palle Holm Olesen
Head of Investor Relations
+45 36 43 24 26
________________________
Stock Exchange Release No 319 - 3 January 2008
About Lundbeck
H. Lundbeck A/S is an international pharmaceutical company engaged in
the research and development, production, marketing and sale of drugs
for the treatment of psychiatric and neurological disorders. In 2006,
the company's revenue was DKK 9.2 billion (approximately EUR 1.2
billion or USD 1.6 billion). The number of employees is approximately
5,300 globally. For further information, please visit
www.lundbeck.com
